These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
513 related articles for article (PubMed ID: 19414633)
1. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias WL; Braunwald E; Sabatine MS Circulation; 2009 May; 119(19):2553-60. PubMed ID: 19414633 [TBL] [Abstract][Full Text] [Related]
2. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275 [TBL] [Abstract][Full Text] [Related]
3. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494 [TBL] [Abstract][Full Text] [Related]
4. Cytochrome p-450 polymorphisms and response to clopidogrel. Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084 [TBL] [Abstract][Full Text] [Related]
5. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770 [TBL] [Abstract][Full Text] [Related]
6. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042 [TBL] [Abstract][Full Text] [Related]
7. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Small DS; Farid NA; Payne CD; Konkoy CS; Jakubowski JA; Winters KJ; Salazar DE Clin Pharmacokinet; 2010 Dec; 49(12):777-98. PubMed ID: 21053990 [TBL] [Abstract][Full Text] [Related]
8. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial. Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Kelly RP; Close SL; Farid NA; Winters KJ; Shen L; Natanegara F; Jakubowski JA; Ho M; Walker JR; Small DS Br J Clin Pharmacol; 2012 Jan; 73(1):93-105. PubMed ID: 21689142 [TBL] [Abstract][Full Text] [Related]
11. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Varenhorst C; James S; Erlinge D; Brandt JT; Braun OO; Man M; Siegbahn A; Walker J; Wallentin L; Winters KJ; Close SL Eur Heart J; 2009 Jul; 30(14):1744-52. PubMed ID: 19429918 [TBL] [Abstract][Full Text] [Related]
12. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027 [TBL] [Abstract][Full Text] [Related]